• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688566.SS
Share

Jiangsu Jibeier Pharmaceutical Co., Ltd. Stocks

CN¥ 27.47Last Updated 15.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 776.09M

CN¥ 27.47
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical enterprise based in Zhenjiang, China, established in 2001. The company's core operations involve the research, development, manufacturing, and sales of a diverse range of pharmaceutical products, including chemical preparations, traditional Chinese medicine formulations, and active pharmaceutical ingredients (APIs). Its product portfolio addresses various health concerns, offering solutions for boosting white blood cell counts, enhancing the immune system, treating joint-related ailments, managing high blood pressure, combating ocular infections, alleviating bronchitis symptoms, and protecting liver function, among others. Additionally, Jiangsu Jibeier is actively engaged in developing new therapeutic drugs, with its pipeline focusing on treatments for conditions such as depression, oncology (tumors), and gastrointestinal disorders.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair value on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 03:25

Apple Is on the Hunt for AI Chip Makers — The Information

16.07.2026 02:05

JPMorgan, BlackRock, and Goldman plan to tokenize stocks and government bonds

16.07.2026 01:11

OpenAI has unveiled its first gadget—a keyboard for controlling AI agents

16.07.2026 00:42

"The rumors are completely false": Lucid denies risk of bankruptcy, shares soar 30%

16.07.2026 00:02

Wall Street's leading tech optimist has launched his own investment bank

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026